|
Synonyms: Ebglyss® | MILR1444A | RG3637 | TNX-650
lebrikizumab is an approved drug (EMA (2023))
Compound class:
Antibody
Comment: Lebrikizumab is a an anti-IL-13 monoclonal antibody.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. |
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes (EMA (2023)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 9165 | lebrikizumab |
| Synonyms |
| Ebglyss® | MILR1444A | RG3637 | TNX-650 |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 325 |
| Other databases | |
| GtoPdb PubChem SID | 223366019 |
| Search PubMed clinical trials | lebrikizumab |
| Search PubMed titles | lebrikizumab |
| Search PubMed titles/abstracts | lebrikizumab |
| Wikipedia | Lebrikizumab |
